Literature DB >> 15620194

[A follow-up study on a randomized, single-blind control of King's Brain pills in treatment of memory disorder in elderly people with MCI in a Beijing community].

Jin-zhou Tian1, Ai-hua Zhu, Jian Zhong.   

Abstract

OBJECTIVE: To evaluate the effect of King's Brain pills (Compound Chinese ginseng extract from herbs) on the treatment and the delaying of memory decline in the elderly with mild cognitive impairment (MCI) in a community by a year follow-up of neuropsychology.
METHOD: 75 patients with MCI were selected from Beixinqiao community of Beijing by a cutoff score of 0.0/0.5 on CDR and were randomly assigned into a treatment group (n = 30 cases), given 4 pills of a compound Chinese ginseng extract (King's Brain) with 2 placebo tablets, and a positive control group (n = 30 cases), given 2 tablets of Piracetam with 4 placebo tablets, as well as a placebo group (n = 15 cases), given a placebo of 4 tablets and 2 pills. All subjects took this medication 3 times a day for 3 months. Single-blind and double-moulding control were used in this study. At a baseline and a middlepoint (after 3 months), and a follow-up end (one year later) following a three months of medication therapeutics, all subjects were assessed using a battery consisting of MMSE and 5 memory items on BNPT battery. RESULT: In the treatment group, MMSE score 27.50 +/- 1.68 was increased to 28.27 +/- 1.70 after 3 months but decreased to 26.90 +/- 1.90 after one year of the treatment. However, the latter score was higher than that in a placebo group 26.33 +/- 1.03 (P < 0.05). Verbal Learning Test score was significantly increased from 68.73 +/- 28.74 at baseline to 87.33 +/- 29.78 at follow-up point in the treatment group, which was significantly higher than that in the placebo group (P < 0.01). The total score of memory items on BNPT battery was significantly increased from 78.23 +/- 28.98 at baseline to 93.53 +/- 35.56 at follow-up point in the treatment group, higher than that in Piracetam group (P < 0.05) and the placebo group (P < 0.01).
CONCLUSION: Both King's Brain spills and piracetam tablets have protective effect on cognitive and memory decline in elderly with MCI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15620194

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  6 in total

Review 1.  The role of phytochemicals in the treatment and prevention of dementia.

Authors:  Melanie-Jayne R Howes; Elaine Perry
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

Review 2.  Treatment for mild cognitive impairment: systematic review.

Authors:  Claudia Cooper; Ryan Li; Constantine Lyketsos; Gill Livingston
Journal:  Br J Psychiatry       Date:  2013-09       Impact factor: 9.319

3.  Chinese Herbal Medicine for Mild Cognitive Impairment: A Systematic Review of Randomized Controlled Trials.

Authors:  Ning Liang; Yaxin Chen; Sihong Yang; Changhao Liang; Lidong Gao; Shang Wang; Yanping Wang; Zhanjun Zhang; Nannan Shi
Journal:  Front Neurol       Date:  2022-06-30       Impact factor: 4.086

4.  Herbal formula GAPT prevents beta amyloid deposition induced Ca(2+)/Calmodulin-dependent protein kinase II and Ca(2+)/Calmodulin-dependent protein phosphatase 2B imbalance in APPV717I mice.

Authors:  Jing Shi; Xuekai Zhang; Long Yin; Mingqing Wei; Jingnian Ni; Ting Li; Pengwen Wang; Jinzhou Tian; Yongyan Wang
Journal:  BMC Complement Altern Med       Date:  2016-06-01       Impact factor: 3.659

5.  Study designs of randomized controlled trials not based on Chinese medicine theory are improper.

Authors:  Jian Yan; Veronica F Engle; Yuxin He; Yan Jiao; Weikuan Gu
Journal:  Chin Med       Date:  2009-02-25       Impact factor: 5.455

6.  GAPT regulates cholinergic dysfunction and oxidative stress in the brains of learning and memory impairment mice induced by scopolamine.

Authors:  Zhenhong Liu; Gaofeng Qin; Lulu Mana; Yunfang Dong; Shuaiyang Huang; Yahan Wang; Yiqiong Wu; Jing Shi; Jinzhou Tian; Pengwen Wang
Journal:  Brain Behav       Date:  2020-03-15       Impact factor: 2.708

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.